Talk:Sirolimus

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Pharmacology (Rated B-class, High-importance)
WikiProject icon This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
B-Class article B  This article has been rated as B-Class on the project's quality scale.
 High  This article has been rated as High-importance on the project's importance scale.
 

Name? Sirolimus vs Rapamycin[edit]

Should the drug really be listed as its trade name, rather than the common chemical one? btavshanjian

I agree, all other drug articles i've seen on WP are under their chemical name, not their trade name, especially since the trade name can differ across countries. --81.205.3.113 (talk) 00:39, 15 July 2009 (UTC)

Looking at popularity, "Rapamycin" produces 11372 records on PubMed, "Sirolimus" gives 8178. I think it also makes sense to have the title of the article be "rapamycin" since the intro paragraph gives the origin of the term "rapa". I don't know how the INN/USAN factor weighes into this arguement. --Tea with toast (talk) 01:36, 29 October 2009 (UTC)

Per WP:MEDMOS, INNs should always be used as article titles. I am a major supporter of this guideline, which is in keeping with the original purpose of INNs—providing a completely unambiguous, internationally recognizable names with no industry or trade connotations. Fvasconcellos (t·c) 03:21, 29 October 2009 (UTC)

If there is complete consensus on this, is the trade name used only because some company PR people are dominating the site? — Preceding unsigned comment added by 75.61.141.90 (talk) 01:28, 20 August 2012 (UTC) In the section on "Autism in Mice" the cited research paper does not mention "Sirolimus" at all, only "Rapamycin" so in the interest of accuracy I changed the names to agree with the citation. — Preceding unsigned comment added by 75.61.141.90 (talk) 01:37, 20 August 2012 (UTC)

Maybe Fvasconcellos didn't make himself entirely clear: "Sirolimus" is not the trade name but the International Nonproprietary Name (INN). Rapamycin is an old name that is still often seen, but we should stick with our guidelines (WP:MOSMED#Drugs, medications and devices) and use the INN, "sirolimus". Also, I think it is confusing to use different names for the same substance, depending on how the respective sources call it -- therefore I'll undo your last edit, although I'm aware you had good intentions. Please tell me (preferably here) if you disagree. Cheers, ἀνυπόδητος (talk) 10:52, 20 August 2012 (UTC)

Autism section[edit]

Is retardism really the best terminology to be used here? —Preceding unsigned comment added by 90.152.14.118 (talk) 09:16, 25 September 2008 (UTC)

I don't think so personally. Standard IQ tests that are used to diagnose and define retardation unfortunately rely heavily on verbal skills. If there is anyone out there that knows of a testing method that defines congnitive ability independantly of verbal skill, I would like to hear of it. It is unfair to those affected by ASD to not separate the two. How to do that may be another question!Melanie.brown35 (talk) 22:19, 29 January 2009 (UTC)

Structure?[edit]

Is the stereochemistry of the structure correct? I'm finding differences in online structures as to what the stereochemistry to the methyl group near the lactone should be. (Hashed bond in upper left) (Also posted on image talk page)-- 16:07, 31 January 2007 (UTC)

I created the image using Image:Sirolimus1.gif as a model, then checked it for accuracy against PubChem 6436030. If the stereochemistry is inaccurate, I apologize; I'll try to find alternate sources and re-check. Fvasconcellos 22:51, 31 January 2007 (UTC)
Apparently it was incorrect. Fixed now, as is the IUPAC name—the one previously in the article was actually for tacrolimus. Thank you. Fvasconcellos 01:25, 1 February 2007 (UTC)

Gimrudghk (talk) 01:25, 27 July 2008 (UTC)Silorimus have several side effects. For example anemia, edema etc.

Sirolimus/ Late Thrombosis[edit]

Inclusion of the statement of the rapamycin DES stent (known as Cypher and sometimes denoted as SES) may be misleading since the exact reason is debatable. One postulate includes what Dr. Renu Virmani at Armed Forces Reseach Laboratories calls a polymer hypersensitivity. If this is correct, then the statement should be included on a Wikipedia page on the Cypher stent and not on the rapamycin/sirolimus page. CClaude 216.140.123.24 (talk) 20:00, 2 December 2008 (UTC)

More precise longevity statement[edit]

"A 2009 study indicated that rapamycin can prolong the life of mice. If this increase in lifespan were translated to human years, it might allow humans to live more than a hundred years". That could use a rewrite. Something like, "If these results were replicable in humans, average lifespan could be extended to over 100 years." 206.223.190.7 (talk) 22:46, 9 July 2009 (UTC)

Cost - use of grapefruit[edit]

A comment regarding the use of grapefruit to lower doses and costs of the drug have been frequently added or removed over the past few months. I have deleted the comment.

Grapefruit (and many other foods) is an inhibitor of CYP450 and will affect the metabolism of many drugs. The CYP450 wiki entry gives more detail.

Grapefruit should not be consumed with Siromilus. Bombauer (talk) 17:11, 5 April 2010 (UTC)Bombauer

Patents[edit]

The referenced US patent 5,665,7220 does not exist, in fact it has one too many digits to be a valid patent number. The earliest US patent referencing rapamycin is 3,929,992 filed in 1974, although 5,675,732 claims a more efficient means of production and would only recently have expired. 199.246.40.54 (talk) 13:46, 6 August 2010 (UTC)

Also 5,212,155 expires in Nov 2010 and 5,100,899 expires Jan 7, 2014 (both re inhibiting transplant rejection) [1] Rod57 (talk) 11:38, 8 October 2010 (UTC)

Removed report of in-vitro work[edit]

Removed from cancer section as not notable (re sirolimus) since only in-vitro :

Panobinostat has been found to synergistically act with sirolimus to kill pancreatic cancer cells in the laboratory in a Mayo Clinic study. In the study, investigators found that this combination destroyed up to 65 percent of cultured pancreatic tumor cells. The finding is significant because the three cell lines studies were all resistant to the effects of chemotherapy-as are many pancreatic tumors.[Removed report of in-vitro work 1]

Rod57 (talk) 11:59, 8 October 2010 (UTC)

References[edit]

Wyeth is now Pfizer[edit]

Shouldn't Wyeth be changed to Pfizer? It should be considering Wyeth's drug portfolio is now owned by Pfizer! — Preceding unsigned comment added by 82.195.117.137 (talk) 10:59, 10 February 2012 (UTC)